Karen Murphy Santiago net worth and biography

Karen Santiago Biography and Net Worth

Karen Murphy Santiago serves as Senior Vice President, Corporate Controller of the Company. She joined Bristol-Myers Squibb Company in 2003 and has served in multiple roles of increasing responsibility. Most recently, from 2012 to 2015 she served as Vice President, Finance for Global Manufacturing and Supply, from 2015 to 2016 as Vice President, Finance for US and Puerto Rico Commercial and since 2016 she has been Vice President, Lead for Enabling Functions and Finance Transformation. Ms. Santiago has an M.B.A. in Finance and a B.S. in Accounting and is a Certified Public Accountant.

What is Karen Murphy Santiago's net worth?: The estimated net worth of Karen Murphy Santiago is at least $180,495.42 as of May 16th, 2019. Ms. Santiago owns 3,066 shares of Bristol-Myers Squibb stock worth more than $180,495 as of November 23rd. This net worth evaluation does not reflect any other investments that Ms. Santiago may own. Learn More about Karen Murphy Santiago's net worth.
How do I contact Karen Murphy Santiago?: The corporate mailing address for Ms. Santiago and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Karen Murphy Santiago's contact information.
Has Karen Murphy Santiago been buying or selling shares of Bristol-Myers Squibb?: Karen Murphy Santiago has not been actively trading shares of Bristol-Myers Squibb within the last three months. Most recently, Karen Murphy Santiago sold 6,577 shares of the business's stock in a transaction on Monday, March 14th. The shares were sold at an average price of $69.19, for a transaction totalling $455,062.63. Learn More on Karen Murphy Santiago's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Samit Hirawat (EVP, Chief Medical Officer and Head of Development), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 6,901 shares worth more than $349,655.16. During the last year, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 700 shares worth more than $38,934.00. The most recent insider tranaction occured on November, 4th when SVP Phil M Holzer sold 700 shares worth more than $38,934.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 11/4/2024.

Karen Murphy Santiago Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/14/2022	Sell	6,577	$69.19	$455,062.63
5/16/2019	Sell	3,065	$47.56	$145,771.40	3,066

Karen Murphy Santiago Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $58.87

$57.62

$58.92

50 Day Range

MA: $53.66

$49.02

$59.82

2 Week Range

Now: $58.87

$39.35

$61.08

Volume

7,412,528 shs

Average Volume

14,364,571 shs

Market Capitalization

$119.40 billion

P/E Ratio

N/A

Dividend Yield

4.12%

Beta

0.44

Trump’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW